PDF 241kWORD 47k

pursuant to Rule 133 of the Rules of Procedure

on research into Alzheimer’s disease

Dominique Bilde

Motion for a European Parliament resolution on research into Alzheimer’s disease  

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to Rule 133 of its Rules of Procedure,

A.  whereas 47 million people, including 6.4 million in the EU, suffer from dementia, and whereas 50 to 70% of these people have Alzheimer’s disease, costing USD 818 billion worldwide, or 1.4% of the GDP of the developed nations (2015);

B  whereas 29.1% of the EU population will be over 65 years old in 2080 and whereas age is the principal risk factor for dementia;

C.  whereas, on 12 June 2018, AstraZeneca and Eli Lilly joined Johnson & Johnson, Pfizer and Merck & Co in abandoning their research into Alzheimer’s disease, and whereas the disputed effectiveness of existing treatments has led to funding being cut in France;

1.  Deplores the decision of the French Ministry of Solidarity and Health referred to in recital C above;

2.  Urges the Commission to finance research for the period 2021-2027, namely the Joint Programme – Neurodegenerative Disease Research (JPND);

3.  Urges the development of national strategies based on the World Health Organisation’s Global action plan on the public health response to dementia (29 May 2017).


Last updated: 3 July 2018Legal notice